

Carbidopa / Levodopa Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.2	06.04.2024	9371560-00007	Date of first issue: 27.08.2021

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1	Product identifier Trade name	:	Carbidopa / Levodopa Formulation
1.2	Relevant identified uses of th	e s	ubstance or mixture and uses advised against
	Use of the Sub- stance/Mixture	:	Pharmaceutical
	Recommended restrictions on use	:	Not applicable
1.3	Details of the supplier of the	safe	ety data sheet
	Company	:	Organon & Co. Shotton Lane NE23 3JU Cramlington NU - Great Britain
	Telephone	:	+44 1 670 59 32 05
	E-mail address of person responsible for the SDS	:	EHSSTEWARD@organon.com

1.4 Emergency telephone number

+1-215-631-6999

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008) as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567)

Acute toxicity, Category 4 Reproductive toxicity, Category 2 Specific target organ toxicity - repeated exposure, Category 1 Long-term (chronic) aquatic hazard, Category 3 H302: Harmful if swallowed.H361d: Suspected of damaging the unborn child.H372: Causes damage to organs through prolonged or repeated exposure.H412: Harmful to aquatic life with long lasting effects.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008) as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567)

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Carbidopa / Levodopa Formulation

Version 4.2	Revision Date: 06.04.2024		Number: 560-00007	Date of last issue: 30.09.2023 Date of first issue: 27.08.2021
Haz	ard pictograms	•		!>
Sigr	al word	: Da	nger	•
Haz	ard statements	: H3 H3 H3 H3	61d Susp 72 Caus repea	nful if swallowed. Tected of damaging the unborn child. Ses damage to organs through prolonged or ated exposure. Inful to aquatic life with long lasting effects.
Prec	cautionary statements	: Pre	evention:	
		P2 P2 P2 P2 P2	60 Do n 70 Do n uct. 73 Avoid 80 Wea	in special instructions before use. ot breathe dust. ot eat, drink or smoke when using this prod- d release to the environment. r protective gloves/ protective clothing/ eye action/ face protection.
		Re	sponse:	
		P3	08 + P313 IF atten	exposed or concerned: Get medical advice/ tion.

Hazardous components which must be listed on the label: Levodopa Carbidopa

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Levodopa	59-92-7 200-445-2	Acute Tox. 4; H302 Repr. 2; H361d STOT RE 1; H372 (Central nervous system)	>= 70 - < 90

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Carbidopa / Levodopa Formulation

Version 4.2	Revision Date: 06.04.2024	SDS Number: 9371560-00007	Date of last issue: 30.09.2023 Date of first issue: 27.08.2021	
			Aquatic Chronic 3; H412	
Carbi	idopa	38821-49-7	Acute Tox. 4; H302 Aquatic Chronic 3; H412	>= 10 - < 20
Subs	tances with a workpla	ce exposure limit :	·	
Cellu	lose	9004-34-6 232-674-9		>= 1 - < 10
Starc	h	9005-25-8 232-679-6		>= 1 - < 10

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice	 In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.
Protection of first-aiders	: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
If inhaled	: If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	 In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	: If in eyes, rinse well with water. Get medical attention if irritation develops and persists.
If swallowed	 If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water. Never give anything by mouth to an unconscious person.
4.2 Most important symptoms a	nd effects, both acute and delayed
Risks	: Harmful if swallowed. Suspected of damaging the unborn child. Causes damage to organs through prolonged or repeated exposure.

Contact with dust can cause mechanical irritation or drying of

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Carbidopa / Levodopa Formulation

Vers 4.2	sion	Revision Date: 06.04.2024		0S Number: 71560-00007	Date of last issue: 30.09.2023 Date of first issue: 27.08.2021			
				the skin. Dust contact with	the eyes can lead to mechanical irritation.			
4.3 I	Indicati	on of any immediate	mec	lical attention and	I special treatment needed			
	Treatment : Treat symptomatically and supportively.							
SEC	CTION	5: Firefighting meas	sur	es				
5.1 I	Extingu	ishing media						
	-	e extinguishing media	:	Water spray Alcohol-resistant Carbon dioxide (C Dry chemical				
	Unsuita media	able extinguishing	:	None known.				
5.2 \$	Special	hazards arising from	the	substance or mix	xture			
	-	c hazards during fire-	:	Avoid generating concentrations, an potential dust exp	dust; fine dust dispersed in air in sufficient nd in the presence of an ignition source is a			
	Hazaro ucts	lous combustion prod-	:	Carbon oxides Metal oxides				
5.3	Advice	for firefighters						
		I protective equipment	:	In the event of fire Use personal prot	e, wear self-contained breathing apparatus. rective equipment.			
	Specifi ods	c extinguishing meth-	:	cumstances and t Use water spray t	measures that are appropriate to local cir- he surrounding environment. o cool unopened containers. ged containers from fire area if it is safe to do			

SECTION 6: Accidental release measures

6.1 Personal precautions, protecti	ve equipment and emergency procedures
Personal precautions	: Use personal protective equipment. Follow safe handling advice (see section 7) and personal pro- tective equipment recommendations (see section 8).
6.2 Environmental precautions	
Environmental precautions	 Avoid release to the environment. Prevent further leakage or spillage if safe to do so.

Retain and dispose of contaminated wash water.

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Carbidopa / Levodopa Formulation

Version 4.2	Revision Date: 06.04.2024	SDS Number: 9371560-00007	Date of last issue: 30.09.2023 Date of first issue: 27.08.2021
			rivers or watercourses, inform the Environ- mergency telephone number 0800 807060).
6.3 Method	is and material for co	ntainment and clean	ing up
Metho	ds for cleaning up	tainer for dispose Avoid dispersal of with compressed Dust deposits sh es, as these may leased into the a Local or national posal of this mat employed in the mine which regu Sections 13 and	of dust in the air (i.e., clearing dust surfaces

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

	•	
Technical measures		tic electricity may accumulate and ignite suspended dust using an explosion.
		bvide adequate precautions, such as electrical grounding d bonding, or inert atmospheres.
Local/Total ventilation		e only with adequate ventilation.
Advice on safe handling		not breathe dust. not swallow.
		bid contact with eyes.
		bid prolonged or repeated contact with skin.
		ish skin thoroughly after handling.
		ndle in accordance with good industrial hygiene and safety
	•	ctice, based on the results of the workplace exposure as-
		nimize dust generation and accumulation.
		ep container closed when not in use.
		ep away from heat and sources of ignition.
		ke precautionary measures against static discharges. not eat, drink or smoke when using this product.
	Ta	ke care to prevent spills, waste and minimize release to the vironment.
Hygiene measures	flus	xposure to chemical is likely during typical use, provide eye shing systems and safety showers close to the working ce. When using do not eat, drink or smoke. Wash contami-
		ed clothing before re-use.
	Th en	e effective operation of a facility should include review of gineering controls, proper personal protective equipment,
	ap	propriate degowning and decontamination procedures,



Carbidopa / Levodopa Formulation

Version 4.2	Revision Date: 06.04.2024	SDS Number: 9371560-00007	Date of last issue: 30.09.2023 Date of first issue: 27.08.2021	
7.2 Cor	ditions for safe storage.	use of administr		
7.2 Conditions for safe storage, including any incompatibilities Requirements for storage areas and containers Keep in properly labelled containers. Store locked up. Store accordance with the particular national regulations.				
Advice on common storage		Strong oxidizing Self-reactive su	Strong oxidizing agents Self-reactive substances and mixtures Organic peroxides Explosives	
	cific end use(s) ecific use(s)	: No data availab	le	

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

dust of any kind

10 mg/m3 Value type (Form of exposure): TWA (Inhalable) Basis: GB EH40

4 mg/m3 Value type (Form of exposure): TWA (Respirable fraction) Basis: GB EH40

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Levodopa	59-92-7	TWA	500 µg/m3 (OEB 2)	Internal
Carbidopa	38821-49-7	TWA	2,000 µg/m3 (OEB 1)	Internal
Cellulose	9004-34-6	TWA (inhalable dust)	10 mg/m3	GB EH40
		TWA (Respirable dust)	4 mg/m3	GB EH40
		STEL (inhalable dust)	20 mg/m3	GB EH40
Starch	9005-25-8	TWA (inhalable dust)	10 mg/m3	GB EH40
		TWA (Respirable dust)	4 mg/m3	GB EH40

8.2 Exposure controls

Engineering measures

Use feasible engineering controls to minimize exposure to compound.



Carbidopa / Levodopa Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.2	06.04.2024	9371560-00007	Date of first issue: 27.08.2021

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Personal protective equipment

Eye/face protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Hand protection Material	:	Chemical-resistant gloves
Skin and body protection Respiratory protection	:	Work uniform or laboratory coat. If adequate local exhaust ventilation is not available or expo- sure assessment demonstrates exposures outside the rec- ommended guidelines, use respiratory protection. Equipment should conform to BS EN 143
Filter type	:	Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Appearance Colour Odour Odour Threshold	:	powder No data available odourless No data available
рН	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, han- dling or other means.
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Relative density	:	No data available



Carbidopa / Levodopa Formulation

Version 4.2	Revision Date: 06.04.2024	SDS Num 9371560-		Date of last issue: 30.09.2023 Date of first issue: 27.08.2021
Dens	sity	: No d	ata availabl	e
Solubility(ies) Water solubility Partition coefficient: n- octanol/water Auto-ignition temperature		: No d	ata availabl ata availabl ata availabl	e
Deco	omposition temperature	: No d	ata availabl	e
Viscosity Viscosity, dynamic		: No d	ata availabl	e
V	iscosity, kinematic	: No d	ata availabl	e
Expl	Explosive properties		explosive	
Oxid	izing properties	: The	substance c	r mixture is not classified as oxidizing.
Flam	r information Imability (liquids) Iccular weight cle size	: No d	ata availabl ata availabl ata availabl	e

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions	: May form explosive dust-air mixture during processing, han- dling or other means. Can react with strong oxidizing agents.
10.4 Conditions to avoid	
Conditions to avoid	: Heat, flames and sparks. Avoid dust formation.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Carbidopa / Levodopa Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.2	06.04.2024	9371560-00007	Date of first issue: 27.08.2021

SECTION 11: Toxicological information

11.1 Information on toxicologica Information on likely routes of exposure		
Acute toxicity Harmful if swallowed.		_);;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
Product: Acute oral toxicity	:	Acute toxicity estimate: 1,952 mg/kg Method: Calculation method
Components:		
Levodopa: Acute oral toxicity	:	LD50 (Rat): 1,780 mg/kg
		LD50 (Mouse): 2,363 mg/kg
Carbidopa:		
Acute oral toxicity	:	
		LD50 (Mouse): 1,750 mg/kg
Cellulose:		
Acute oral toxicity	:	LD50 (Rat): > 5,000 mg/kg
Acute inhalation toxicity	:	LC50 (Rat): > 5.8 mg/l Exposure time: 4 h Test atmosphere: dust/mist
Acute dermal toxicity	:	LD50 (Rabbit): > 2,000 mg/kg
Starch:		
Acute oral toxicity	:	LD50 (Rat): > 5,000 mg/kg
Acute dermal toxicity	:	LD50 (Rabbit): > 2,000 mg/kg
Skin corrosion/irritation Not classified based on availa	ble	information.
Components:		
Carbidopa: Species Result	:	Rabbit No skin irritation

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Carbidopa / Levodopa Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.2	06.04.2024	9371560-00007	Date of first issue: 27.08.2021

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Carbidopa:

Species Result : Rabbit : Mild eye irritation

Starch:

Species	:	Rabbit
Result	:	No eye irritation

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

Levodopa:

•		
Species	:	Guinea pig
Result	:	Not a skin sensitizer.

Carbidopa:

Remarks

: No data available

Starch:

Test Type	:	Maximisation Test
Exposure routes	:	Skin contact
Species	:	Guinea pig
Result	:	negative

Germ cell mutagenicity

Not classified based on available information.

Components:

Levodopa:

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES)
	Result: negative

Test Type: Chromosomal aberration Test system: mouse lymphoma cells Result: equivocal

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Carbidopa / Levodopa Formulation

ersion .2	Revision Date: 06.04.2024	SDS Number: 9371560-00007	Date of last issue: 30.09.2023 Date of first issue: 27.08.2021
		Test Type: Micr Test system: C Result: positive	hinese hamster lung cells
			er chromatid exchange assay hinese hamster lung cells
Carbi	dopa:		
	toxicity in vitro	: Test Type: Bac Result: positive	terial reverse mutation assay (AMES)
		Test Type: In vi Result: positive	tro mammalian cell gene mutation test
Genot	toxicity in vivo	: Test Type: Micr Species: Mouse Application Rou Result: negative	e ite: Oral
Cellul	lose:		
Genot	toxicity in vitro	: Test Type: Bac Result: negative	terial reverse mutation assay (AMES) e
		Test Type: In vi Result: negative	tro mammalian cell gene mutation test e
Genot	toxicity in vivo	: Test Type: Mar cytogenetic ass Species: Mouse Application Rou Result: negative	e ite: Ingestion
Starc	h.		
	toxicity in vitro	: Test Type: Bac Result: negative	terial reverse mutation assay (AMES) e
	nogenicity assified based on av	ailable information.	
Comp	oonents:		
Levo	dopa:		
Speci		: Rat	
Applic	ation Route	: Oral	
	sure time	: 2 Years	
Expos Resul	t	: negative	
Resul	t dopa:	. negative	

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Carbidopa / Levodopa Formulation

Version 4.2	Revision Date: 06.04.2024	SDS Number: 9371560-00007	Date of last issue: 30.09.2023 Date of first issue: 27.08.2021
	lication Route osure time sult	: Oral : 96 weeks : 135 mg/kg bo : negative	dy weight
Spe App	lulose: ecies elication Route osure time sult	: Rat : Ingestion : 72 weeks : negative	
Sus	productive toxicity pected of damaging the nponents:	unborn child.	
	odopa: ects on fertility		
Effe mei	ects on foetal develop- nt		bit oute: Oral al Toxicity: LOAEL: 125 mg/kg body weight keletal malformations, Visceral malformations
		Test Type: De Species: Rat Application R Development	
			se oute: Oral al Toxicity: LOAEL: 500 mg/kg body weight ffects on foetal development
-	productive toxicity - As- sment	: Some eviden animal experi	ce of adverse effects on development, based on ments.
Car	bidopa:		
	ects on fertility		



Carbidopa / Levodopa Formulation

Vers 4.2	sion	Revision Date: 06.04.2024		DS Number: 71560-00007	Date of last issue: 30.09.2023 Date of first issue: 27.08.2021
				Result: Animal te	sting did not show any effects on fertility.
	Effects ment	s on foetal develop-	:	Test Type: Devel Species: Mouse Application Route Developmental T Result: No terato	e: Oral oxicity: NOAEL: 120 mg/kg body weight
				Test Type: Devel Species: Rabbit Application Route Developmental T Result: No terato	e: Oral oxicity: NOAEL: 120 mg/kg body weight
	Cellul	ose:			
	Effects	s on fertility	:	Test Type: One-o Species: Rat Application Route Result: negative	generation reproduction toxicity study e: Ingestion
	Effects ment	s on foetal develop-	:	Test Type: Fertili Species: Rat Application Route Result: negative	ty/early embryonic development e: Ingestion
	стот	- single exposure			
	Not cla	assified based on avail	able	information.	
		- repeated exposure			
		s damage to organs th	roug	an proionged or rep	beated exposure.
		onents:			
	Levod	-		Oral	
		ure routes Organs	-	Oral Central nervous s	system
	A			0	

ntrai nervous system : Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Levodopa:

Assessment

Species LOAEL Application Route Exposure time Target Organs	: : :	Rat 100 mg/kg Oral 106 Weeks Central nervous system
Symptoms Species		Salivation Monkey

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Carbidopa / Levodopa Formulation

rsion	Revision Date: 06.04.2024	SDS Number: 9371560-00007	Date of last issue: 30.09.2023 Date of first issue: 27.08.2021
LOAE	L	: 100 mg/kg	
Applic	ation Route	: Oral	
	ure time	: 22 Weeks	
Target	t Organs	: Central nervo	bus system
Carbie	dopa:		
Specie	es	: Rat	
LÖAE	L	: 25 mg/kg	
Applic	ation Route	: Oral	
	ure time	: 96 Weeks	
Rema	rks	: No significant	adverse effects were reported
Specie		: Monkey	
NOAE		: 135 mg/kg	
	ation Route	: Oral	
	ure time	: 1 yr	
Rema	rks	: No significant	adverse effects were reported
Specie	es	: Dog	
NOAE		: 5 mg/kg	
LOAE		: 15 mg/kg	
	ation Route	: Oral	
	ure time	: 238 d	
Sympt	toms	: Diarrhoea, Vo	omiting, Tremors
Cellul	ose:		
Specie	es	: Rat	
NOAE		: >= 9,000 mg/	kg
	ation Route	: Ingestion	
Expos	ure time	: 90 Days	
Starch	ו:		
Specie	es	: Rat	
NOAE	Ľ	: >= 2,000 mg/	kg
	ation Route	: Skin contact	
Expos	ure time	: 28 Days	
Metho	d	: OECD Test 0	Guideline 410
Aspira	ation toxicity		
	assified based on av		
Exper	ience with human e	exposure	
<u>Comp</u>	onents:		
Levod	-		
Ingest	ion	: Symptoms: N ness	lausea, central nervous system effects, Drowsi-
Carbie	dopa:		
Ingest	ion	: Symptoms: ir	voluntary movement

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Carbidopa / Levodopa Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.2	06.04.2024	9371560-00007	Date of first issue: 27.08.2021

SECTION 12: Ecological information

12.1 Toxicity

Components:

Levodopa:

Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 16 mg/l Exposure time: 48 h
Carbidopa: Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 35.3 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Cellulose: Toxicity to fish	:	LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l Exposure time: 48 h

Remarks: Based on data from similar materials

12.2 Persistence and degradability

Components:	
Cellulose:	
Biodegradability	: Result: Readily biodegradable.

cumulativo potontial 3 Bio 12

12.3 Bioaccumulative potential	
Components:	
Levodopa: Partition coefficient: n- : octanol/water	log Pow: -2.39
12.4 Mobility in soil	
No data available	
12.5 Results of PBT and vPvB asse	essment
Product:	
Assessment :	This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
12.6 Other adverse effects	
Product: Endocrine disrupting poten- :	This substance/mixture does not contain components consid-



Carbidopa / Levodopa Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.2	06.04.2024	9371560-00007	Date of first issue: 27.08.2021
tial			docrine disrupting properties for environment K REACH Article 57(f).

SECTION 13: Disposal considerations

13.1 Waste treatment methods	
Product	 Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.
Contaminated packaging	 Empty containers should be taken to an approved waste han- dling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number

ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
ΙΑΤΑ	:	Not regulated as a dangerous good
14.2 UN proper shipping name		
ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
ΙΑΤΑ	:	Not regulated as a dangerous good
14.3 Transport hazard class(es)		
ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
ΙΑΤΑ	:	Not regulated as a dangerous good
14.4 Packing group		
ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good



Carbidopa / Levodopa Formulation

Version 4.2	Revision Date: 06.04.2024	•-	DS Number: 371560-00007	Date of last issue: 30.09.2023 Date of first issue: 27.08.2021	
RID		:	Not regulated as	a dangerous good	
IMDG		:	Not regulated as a dangerous good		
IATA (Cargo)		:	Not regulated as a dangerous good		
IATA (Passenger)		:	Not regulated as a dangerous good		
14.5 Environmental hazards Not regulated as a dangerous good					
14.6 Special precautions for user Not applicable					

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks	: Not applicable for product as sup	plied.
---------	-------------------------------------	--------

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

Relevant EU provisions transposed through retained EU law

UK REACH List of restrictions (Annex 17) UK REACH Candidate list of substances of very high concern (SVHC) for Authorisation	:	Not applicable Not applicable			
The Persistent Organic Pollutants Regulations (retained Regulation (EU) 2019/1021 as amended for Great Britain)	:	Not applicable			
Regulation (EC) No 1005/2009 on substances that deplete the ozone layer	:	Not applicable			
UK REACH List of substances subject to authorisation (Annex XIV)	:	Not applicable			
GB Export and import of hazardous chemicals - Prior Informed Consent (PIC) Regulation	:	Not applicable			
Control of Major Accident Hazards Regulations 2015 (COMAH) Not applicable					

Other regulations:

Take note of The Management of Health and Safety at Work Regulations 1999 (requirements relating to new and expectant mothers at work contained in Regulation 16 to 18) and of the Pregnant Workers Directive 92/85/EEC.

Take note of The Management of Health and Safety at Work Regulations 1999 (requirements relating to protection of young people at work contained in Regulation 19) and of Directive 94/33/EC on the protection of young people at work.

The components of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Carbidopa / Levodopa Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.2	06.04.2024	9371560-00007	Date of first issue: 27.08.2021

15.2 Chemical safety assessment

Full text of H-Statements

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information					
Other information :	Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.				

H302 H361d	:	Harmful if swallowed. Suspected of damaging the unborn child.	
H372		Causes damage to organs through prolonged or repeated exposure if swallowed.	
H412	:	Harmful to aquatic life with long lasting effects.	
Full text of other abbreviations			

Acute Tox.	:	Acute toxicity
Aquatic Chronic	:	Long-term (chronic) aquatic hazard
Repr.	:	Reproductive toxicity
STOT RE	:	Specific target organ toxicity - repeated exposure
GB EH40	:	UK. EH40 WEL - Workplace Exposure Limits
GB EH40 / TWA	:	Long-term exposure limit (8-hour TWA reference period)
GB EH40 / STEL	:	Short-term exposure limit (15-minute reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways: ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance: PICCS - Philippines Inventory of Chemicals and Chemical Substances: (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet;



Carbidopa / Levodopa Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.2	06.04.2024	9371560-00007	Date of first issue: 27.08.2021

SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to :	Internal technical data, data from raw material SDSs, OECD
compile the Safety Data	eChem Portal search results and European Chemicals Agen-
Sheet	cy, http://echa.europa.eu/

Classification of the mixtur	Classification procedure:	
Acute Tox. 4	H302	Calculation method
Repr. 2	H361d	Calculation method
STOT RE 1	H372	Calculation method
Aquatic Chronic 3	H412	Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

GB / EN